Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Recarbrio Generic Name & Formulations
Legal Class
Rx
General Description
Imipenem 500mg, cilastatin sodium 500mg, relebactam 250mg; per vial; pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Carbapenem (thienamycin) + dehydropeptidase I inhibitor + beta-lactamase inhibitor.
How Supplied
Single-dose vials—25
Manufacturer
Generic Availability
NO
Recarbrio Indications
Indications
Susceptible infections including hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP); complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis in those who have limited or no alternative treatment options.
Recarbrio Dosage and Administration
Adult
Give by IV infusion over 30mins. ≥18yrs: 1.25g every 6hrs. Duration of therapy: 4–14 days (based on severity or location of infection). Renal impairment (CrCl 60–89mL/min): 1g every 6hrs; (CrCl 30–59mL/min): 0.75g every 6hrs; (CrCl 15–29mL/min) or (ESRD on hemodialysis): 0.5g every 6hrs; (CrCl <15mL/min): not recommended unless hemodialysis is started within 48hrs. Hemodialysis: give after session (see full labeling).
Children
<18yrs: not established.
Recarbrio Contraindications
Not Applicable
Recarbrio Boxed Warnings
Not Applicable
Recarbrio Warnings/Precautions
Warnings/Precautions
Discontinue immediately if hypersensitivity reaction occurs. Compromised renal function. CNS disorders (eg, brain lesions, history of seizures). Perform neurological evaluation if CNS reactions (eg, seizures, confusional states, myoclonic activity) occur. Risk of C. difficile-associated diarrhea; discontinue and treat if colitis is suspected or confirmed. Elderly. Pregnancy. Nursing mothers.
Recarbrio Pharmacokinetics
See Literature
Recarbrio Interactions
Interactions
Avoid concomitant valproic acid or divalproex sodium; consider alternatives other than carbapenems. Concomitant ganciclovir: not recommended.
Recarbrio Adverse Reactions
Adverse Reactions
Diarrhea, nausea, headache, vomiting, ALT/AST increased, phlebitis/infusion site reactions, pyrexia, hypertension, anemia, hypokalemia, hyponatremia; CNS reactions, C. difficile-associated diarrhea.
Recarbrio Clinical Trials
See Literature
Recarbrio Note
Not Applicable
Recarbrio Patient Counseling
See Literature
